|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma显示文摘 | Florian Hucke Matthias Pinter Ivo Graziadei Simona Bota Wolfgang Vogel Christian Müller Harald Heinzl Fredrik Waneck Michael Trauner Markus Peck-Radosavljevic Wolfgang Sieghart | 2014 | Journal of Hepatology2014，，： | 2 |
| 2 | Review of GPI-anchored membrane proteins显示文摘 | BROWN D WANECK G L | 1992 | J Am Soc Nephrol1992，，3： | 1 |
| 3 | Sociopsychological corre- lates of motivation to quit smoking among low-SES African American women 显示文摘 | Manfredi C Lacey LP Wanecke R | 1998 | Health Educ Behav1998，25，3： | 1 |
| 4 | Natural killer cells in xenotransplantation显示文摘 | Seebach JD Waneck GL | 1997 | Xenotransplantation1997，4，4： | 1 |
| 5 | Identification of the reg ion on the class Ⅰ histocompatibility molecule that interacts with the molecular chaperone,p88(calnexin,IP90)显示文摘 | MAROLESE L WANECK GL SUZUKI GL | 1993 | J Biol Chem1993，268，： | 1 |
| 6 | Glycosyl-phosphatidylinositolanchored membrane proteins显示文摘 | Brown D Waneck G L | 1992 | J Am Soc Nephrol1992，3，4： | 1 |
| 7 | Glycosyl-phosphatidylinositol-anchored membrane proteins显示文摘 | Brown D Waneck GL | 1992 | J Am Soc Nephrol1992，3，4： | 1 |
| 8 | Up-regula- tion of Survivin Mrna might be a marker for non-invasive de- tection of non-small cell lung cancer rather than for prognosis 显示文摘 | Wanecke EU taldus SE Bollsehweiler E | 2008 | Anticancer Res2008，28，3： | 1 |
| 9 | Embolization of Bone Metastases显示文摘 | Peter P. Barton Reinhart E. Waneck Franz J. Karnel Peter Ritschl Josef Kramer Gerhard L. Lechner | 1996 | Journal of Vascular and Interventional Radiology1996，，： | 1 |
| 10 | The relation- ship between the common femoral artery, the inguinal crease, and the inguinal ligament: a guide to accurate angiographic puncture 显示文摘 | Lechner G Jantsch H Waneck R | 1988 | Cardiovasc Intervent Radiol1988，11，3： | 1 |
| 11 | Altered expression of Ly-49 receptors on NK cells developing in mixed allogeneic bone marrow chimeras显示文摘 | MANILAY J O WANECK G L SYKES M | 1998 | Int Immunol1998，10，： | 1 |
| 12 | Glycosyl-phosphatidylinositol-anehored membrane proteins 显示文摘 | Brown D Waneck GL | 1992 | J Am Soc Nephrol1992，3，4： | 1 |
| 13 | Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase Ⅱ trial EXACT显示文摘Objective: Advances in high-throughput genomic profiling and the development of new targeted therapies improve patient's survival. In gastrointestinal(GI) malignancies, the concept of personalized medicine(PM) was not investigated so far. The aim of this prospective study was to evaluate the efficacy of a personalized treatment in GI patients who failed standard treatment.Methods: Out of the original prospective clinical phase Ⅱ EXACT trial, 21(38%) GI cancer patients who had no further treatment options were identified. A molecular profile(MP) via a 50 gene next generation sequencing(NGS) panel in combination with immunohistochemistry(IHC) was conducted using real-time biopsy tumor material. Results were discussed by a multidisciplinary team(MDT) to translate the individual MP in an experimental treatment.Results: Of the 55 patients originally included in the EXACT trial, 21(38%) suffered from GI malignancies.The final analysis showed that 15(71%) patients had experienced a longer progression-free survival(PFS) upon experimental targeted treatment(124 d, quartiles 70/193 d), when compared with the PFS achieved by the previous conventional therapy(62 d, quartiles 55/83 d)(P=0.014). Thirteen(62%) patients receiving targeted treatment experienced a disease control according to Response Evaluation Criteria in Solid Tumors(RECIST). Median overall survival(OS) from the start of experimental therapy to time of censoring or death was 193 d(quartiles115/374 d).Conclusions: PM was not investigated in GI malignancies so far in a prospective trial. This study shows that treatment based on real-time molecular tumor profiling led to a superior clinical benefit, and survival as well as response was significantly improved when compared with previous standard medications. | Matthias Unseld Robert Mader Lukas Baumann Clarence Veraar Fritz Wrba Fredrik Waneck Markus Kieler Daniela Bianconi Walter Berger Maria Sibilia Leonhard Miillauer Christoph Zielinski Gerald W. Prager | 2018 | Chinese Journal of Cancer Research2018，30，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员